Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20030270HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS20029525HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS20029526HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS20029527HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS20030523HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS20030524HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS20030525HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS20030526HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS44015804HTLV-1ENSG00000115232.14protein_codingITGA4NoNo3676P13612
TCGA Plot Options
Drug Information
GeneITGA4
DrugBank IDDB09033
Drug NameVedolizumab
Target IDBE0000590
UniProt IDP13612
Regulation Typeantibody
PubMed IDs19509315
CitationsSoler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER: The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. doi: 10.1124/jpet.109.153973. Epub 2009 Jun 9.
GroupsApproved
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBLCHEMBL1743087